发明名称 |
TREATMENT OF CANCERS EXPRESSING P95 ERBB2 |
摘要 |
The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95ErbB2 inhibitor, and methods of treating such patients. |
申请公布号 |
WO2005011607(A3) |
申请公布日期 |
2005.07.21 |
申请号 |
WO2004US24888 |
申请日期 |
2004.08.02 |
申请人 |
SMITHKLINE BEECHAM CORPORATION;SPECTOR, NEIL, LEE;XIA, WENLE |
发明人 |
SPECTOR, NEIL, LEE;XIA, WENLE |
分类号 |
A61K;A61K31/519;A61K38/00;C07K2/00;C07K4/00;C07K5/00;C07K7/00;C07K14/00;C07K16/00;C07K17/00;G01N33/574 |
主分类号 |
A61K |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|